- Who We Are
- Clinician Employment
- Publications
- Witness to Witness (W2W)
- El Premio Kugel & Zuroweste a la Justicia en la Salud
- Your Voice Matters: Photovoice Project
Candlelighters Childhood Cancer Family Alliance
Provides emotional, educational, and practical support to children with cancer and their families in the Houston, TX area
CDC Division of Tuberculosis Self Study Modules on Tuberculosis
CDC Division of Tuberculosis Self Study Modules on Tuberculosis
CDC Division of Tuberculosis Self Study Modules on Tuberculosis
CDC Division of Tuberculosis Self Study Modules on Tuberculosis
CDC Health Alert. CDC recommends against the use of Amantadine and Rimandatine for the Treatment or Prophylaxis of Influenza in the US during the 2005–06 Influenza Season. January 17, 2006.
CDC Health Alert. CDC recommends against the use of Amantadine and Rimandatine for the Treatment or Prophylaxis of Influenza in the US during the 2005–06 Influenza Season. January 17, 2006.
CDC Health Alert. CDC recommends against the use of Amantadine and Rimandatine for the Treatment or Prophylaxis of Influenza in the US during the 2005–06 Influenza Season. January 17, 2006.
CDC Health Alert. CDC recommends against the use of Amantadine and Rimandatine for the Treatment or Prophylaxis of Influenza in the US during the 2005–06 Influenza Season. January 17, 2006.
CDC issues ACIP recommendations for the use of HPV vaccine
These recommendations represent the first statement by the
Advisory Committee on Immunization Practices (ACIP) on the use
of a quadrivalent human papillomavirus (HPV) vaccine licensed by
the U.S. Food and Drug Administration on June 8, 2006. This
report summarizes the epidemiology of HPV and associated
diseases, describes the licensed HPV vaccine, and provides
recommendations for its use for vaccination among females aged
9-26 years in the United States. March 2007.
